Virtual Hallway recently hosted a dynamic webinar to kick off the academic year, focusing on simplifying Chronic Kidney Disease (CKD) management in patients with type 2 diabetes. Led by nephrologist Dr. David Cherney and moderated by Dr. Jacob Cookey, the session reviewed new strategies for improving patient outcomes.
The webinar spotlighted the FLOW study, which examined how innovative diabetes treatments can prevent kidney-related complications. Dr. Cherney emphasized the study’s findings, showing how early intervention with SGLT2 inhibitors can slow CKD progression and improve patient quality of life.
FLOW Study Insights: SGLT2 inhibitors not only manage diabetes but also offer substantial kidney protection, delaying advanced CKD.
Proactive Management: Early detection and intervention, based on FLOW data, lead to better patient outcomes and reduced need for invasive treatments.
Personalized Care: Treatment must be tailored, considering individual kidney function and diabetes control.
Collaborative Approach: A multidisciplinary team of specialists and primary care providers is crucial for effective CKD management.
During the Q&A, participants asked about real-world application. When addressing concerns over SGLT2 inhibitor side effects or costs, Dr. Cherney stressed the importance of patient education and alternative access options. He also noted the significant role diet plays in CKD management, advising small, patient-friendly dietary adjustments in collaboration with dietitians.
Watch the full session on-demand, learn how the FLOW study is reshaping CKD and diabetes care and claim your MainPro+ credit.
Disclaimer: The lecture and all related materials are provided for educational purposes only and do not constitute medical advice. They are not intended to be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare provider for advice regarding any medical condition or treatment.
